BAD HOMBURG, Germany, Dec. 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has been recognized as a sustainability leader with the inclusion in the Dow Jones Sustainability World Index and with the inclusion in the Dow Jones Sustainability Europe Index for the 15th time. Dow Jones Sustainability Index (DJSI) is one of the world's leading ESG (Environmental, Social, Governance) stock indices.

BAD HOMBURG, Germany, Dec. 20, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, will return to the top tier of the German Stock Index, the DAX 40, as of December 27, 2024. The index represents the performance of the 40 largest publicly traded companies listed on the Frankfurt Stock Exchange and accounts for around 80 percent of the market capitalization of listed stock corporations in Germany.

BAD HOMBURG, Germany, Nov. 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced its heart and lung group has been awarded a national group purchasing agreement for Mechanical Circulatory Support with Premier, Inc in the U.S. Since acquiring Xenios in 2016, Fresenius Medical Care has been dedicated to advancing heart and lung therapy. The agreement underscores FME's commitment to critical care solutions and allows Premier member hospitals and health systems, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the Novalung System.

BAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The Care Delivery margin extended well into the 2025 margin target band while Care Enablement maintained the significant margin progress realized in the first half year. Our clear focus on improving operational performance and continued momentum of FME25 savings realization supported our progress in the third quarter", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "In Care Delivery, a very important and reassuring milestone was underlying U.S. same market treatment growth turning positive. Care Enablement recorded solid volume growth and continued positive pricing momentum outside China." Giza added: "In light of the developments in the first nine months, we confirm our revenue growth outlook and tighten our operating income1 growth outlook with 16-18% toward the upper end of the previous range for the full year 2024."

WALTHAM, Mass., Sept. 4, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), a global leader in kidney care, has achieved a growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis (HHD) therapy through both Fresenius Kidney Care clinics and other providers. The company has in parallel launched the newest version of its home dialysis machine, the NxStage® Versi®HD with GuideMe Software, featuring enhancements designed to simplify treatment, increase ease of learning, and improve user experience. These achievements highlight the efficacy and reliability of the NxStage system in delivering safe, high-quality care to patients in the comfort of their homes.

BAD HOMBURG, Germany, June 12, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emissions in its own operations (Scope 1 and 2) by 50 percent by 2030.

BAD HOMBURG, Germany, Jan. 8, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program. Refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of a disciplined and stringent approach to capital allocation.